Case Investigations

Mazor Robotics Ltd.

June 20, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Mazor Robotics Ltd. (“Mazor” or the “Company”) (NASDAQ: MZOR).

Booz Allen Hamilton Holding Corporation

June 16, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Booz Allen Hamilton Holding Corporation (“Booz Allen” or the “Company”) (NYSE: BAH).  Investors who purchased shares of Booz Allen securities may be affected.

Synchronoss Technologies, Inc.

June 14, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR).  Investors who purchased shares of Synchronoss securities may be affected.

Dick's Sporting Goods, Inc.

May 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Dick’s Sporting Goods, Inc. (“Dick’s” or the “Company”) (NYSE: DKS).

Akari Therapeutics, PLC

May 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Akari Therapeutics, PLC (“Akari” or the “Company”) (NASDAQ: AKTX).

Barrick Gold Corp.

May 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Barrick Gold Corporation (“Barrick” or the “Company”) (NYSE: ABX).

Sunrun, Inc.

May 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Sunrun Inc.  (“Sunrun” or the “Company”) (NASDAQ: RUN).

Anadarko Petroleum Corporation

May 19, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Anadarko Petroleum Corporation. (“Anadarko” or the “Company”) (NYSE: APC).

Intra-Cellular Therapies, Inc.

May 2, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (“Intra-Cellular Therapies” or the “Company”) (NASDAQ: ITCI).  Investors who purchased shares of Intra-Cellular common stock may be affected.

Lion Biotechnologies, Inc.

April 25, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Lion Biotechnologies, Inc. (“Lion” or the “Company”) (NASDAQ: LBIO).

Celadon Group, Inc.

April 20, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Celadon Group, Inc. (“Celadon” or the “Company”) (NYSE:  CGI).

Vince Holding Corp.

April 19, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Vince Holding Corp. ("Vince” or the "Company") (NYSE: VNCE) for potential violations of the federal securities laws.  Investors who purchased Vince common stock may be affected.

Toronto-Dominion Bank, Inc. (TD Bank)

April 7, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of The Toronto-Dominion Bank (“TD Bank” or the “Company”) (NYSE:TD).  A class action complaint has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of TD Bank securities between December 3, 2015 and March 9, 2017, inclusive (the “Class”), alleging violations of the Securities Exchange Act of 1934 (the “Exchange Act”).

FTD Companies, Inc.

March 28, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of FTD Companies, Inc. (“FTD” or the “Company”) (NASDAQ:  FTD).

AmTrust Financial Services, Inc.

March 17, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of AmTrust Financial Services, Inc. (“AmTrust” or the “Company”) (NASDAQ: AFSI).  Investors who purchased shares of AmTrust securities may be affected.

Netflix, Inc.

March 15, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Netflix, Inc. (“Netflix” or the “Company”) (NASDAQ:  NFLX).

Pearson, plc.

March 7, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Pearson, plc. (“Pearson” or the “Company”) (NYSE:  PSO).

Invuity, Inc.

March 7, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Invuity, Inc. (“Invuity” or the “Company”) (NASDAQ:  IVTY).

NCI, Inc.

January 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of NCI, Inc. (“NCI” or the “Company”) (NASDAQ: NCIT).  Investors who purchased shares of NCI common stock prior to January 23, 2017 may be affected.

Banc of California, Inc.

January 23, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Banc of California, Inc. (“Banc of California” or the “Company”) (NYSE: BANC).  Investors who purchased shares of Banc of California common stock prior to January 23, 2017 may be affected.

Gigamon, Inc.

January 19, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Gigamon, Inc. (“Gigamon” or the “Company”) (NYSE: GMO). Investors who purchased shares of Gigamon common stock during the period October 28, 2016 through January 17, 2017 may be affected.

DaVita, Inc.

January 10, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating DaVita Inc. ("DaVita” or the "Company") (NYSE: DVA) for potential violations of the federal securities laws.  Investors who purchased DaVita common stock may be affected.

Inovalon Holdings, Inc.

December 13, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Inovalon Holdings, Inc. ("Inovalon” or the "Company") (NASDAQ: INOV) for potential violations of the federal securities laws.  Investors who purchased Inovalon securities may be affected.

Trinity Biotech plc

October 19, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Trinity Biotech plc. ("Trinity” or the "Company") (NASDAQ: TRIB), a company developing medical diagnostics products, for potential violations of the federal securities laws.  Investors who purchased Trinity’s American Depositary Receipts (“ADRs”) between December 17, 2015 and October 3, 2016 may be affected.

Opus Bank

October 19, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Opus Bank (“Opus”) (NASDAQ: OPB) for potential violations of the federal securities laws.  Investors who purchased Opus Bank securities between February 26, 2015 and October 18, 2016 (the “Class Period”) may be affected.

Ferrellgas Partners, L.P.

October 11, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Ferrellgas Partners, L.P. ("Ferrellgas” or the "Company") (NYSE: FGP) for potential violations of the federal securities laws.  Investors who purchased Ferrellgas securities between June 1, 2015 and September 28, 2016 (the “Class Period”) may be affected.

Centene Corp.

August 31, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Centene Corp. (“Centene” or the "Company") (NYSE: CNC).  Investors who purchased Centene securities between June 17, 2016 and July 25, 2016 may be affected.

Immunomedics, Inc.

June 3, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Immunomedics, Inc. (“Immunomedics” or the “Company”) (Nasdaq: (IMMU).  Investors who purchased Immunomedics securities between May 4, 2016 and June 2, 2016 may be affected.

Credit Acceptance Corporation

May 4, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Credit Acceptance Corporation ("Credit Acceptance” or the "Company") (NASDAQ: CACC), a subprime auto lender, for potential violations of the federal securities laws.  Investors who purchased shares of Credit Acceptance common stock may be affected.

Natus Medical Incorporated

April 10, 2016 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating Natus Medical Incorporated (“Natus” or the "Company") (Nasdaq: BABY).  Investors who purchased Natus securities between October 15, 2015 and April 1, 2016 may be affected.